Menelas Pangalos - AstraZeneca PLC Executive Vice President - Innovative Medicines
| AZNCF Stock | USD 153.42 1.22 0.79% |
President
Mr. Menelas Pangalos is an Executive Vice President Research Development BioPharmaceuticals of AstraZeneca PLC. He was appointed as Executive VicePresident, RD BioPharmaceuticals in January 2019 and is responsible for RD from discovery through to latestage development for CVRM and Respiratory. Prior to this, he served as Executive VicePresident of AstraZenecas IMED Biotech Unit and Global Business Development. Since joining AstraZeneca in 2010, Mene has led a transformation of our RD productivity and has championed an open approach to working with academic and other external partners. Mene previously held senior RD roles at Pfizer, Wyeth and GSK. Mene holds an Honorary PhD from Glasgow University and is a Fellow of the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge. He sits on the Medical Research Council, cochairs the Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the Life Sciences Industrial Strategy Implementation Board and National Genomics Board. He is also a Board member of the British Pharmaceutical Group and Cambridge Universitys Judge Business School. since 2019.
| Age | 56 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | PRESIDENT Age | ||
| Yoshitsugu Shitaka | Astellas Pharma | N/A | |
| Yoshitsugu Shitaka | Astellas Pharma | N/A | |
| David Bell | Grifols SA ADR | 71 | |
| Sergio Adell | Grifols SA ADR | 57 | |
| JeanBaptiste Chatillon | Sanofi ADR | 59 | |
| Antonio Martinez | Grifols SA ADR | 58 | |
| Hiroyuki Okuzawa | Daiichi Sankyo | 61 | |
| Miguel Montblanch | Grifols SA ADR | 64 | |
| Alberto Roura | Grifols SA ADR | 65 | |
Management Performance
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 |
AstraZeneca PLC Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, CFO and Executive Director | ||
| Chris Sheldon, Head Relations | ||
| Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
| MBA DVM, CEO Director | ||
| Gonzalo Vina, Head Relations | ||
| Aradhana MD, CFO Director | ||
| Menelas Pangalos, Executive Vice President - Innovative Medicines | ||
| Katarina Ageborg, Chief Compliance Officer | ||
| Jeffrey Pott, General Counsel | ||
| Ruud Dobber, Executive Vice President Europe |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 241.1 B | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 48.84 % | |||
| Price To Earning | 44.18 X | |||
| Price To Book | 6.16 X |
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Pink Sheet
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.